Ards guideline based management in detail,provide newer guidelines
Reading File
Finding Sources
Searching PubMed
"acute respiratory distress syndrome" AND management
Searching the Web
ARDS management guidelines 2024 2025 ESICM ATS updated recommendations
Reading File
Reading Article
PMID: 38032683
Reading Web Page
https://reference.medscape.com/cc2/p10/management-acute-resp…
Finding Sources
Searching PubMed
"acute respiratory distress syndrome" AND "prone position" AND "PEEP"
Searching the Web
ESICM 2023 ARDS guidelines phenotyping VV-ECMO prone position recommendations Grasselli
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Can u give the details or not
I have enough information from the research already gathered. Let me give you the comprehensive answer now.
ARDS: Guideline-Based Management (ATS 2024 + ESICM 2023)
1. DEFINITION - Berlin Criteria (2012, still current; expanded 2024)
| Severity | PaO2/FiO2 ratio | Mortality |
|---|---|---|
| Mild | 200-300 mmHg (with PEEP ≥5) | ~27% |
| Moderate | 100-200 mmHg | ~32% |
| Severe | <100 mmHg | ~45% |
Diagnostic requirements (all 4 must be met):
- Acute onset within 7 days of a known clinical insult
- Bilateral opacities on CXR/CT not fully explained by effusions, collapse, or nodules
- PaO2/FiO2 <300 on PEEP ≥5 cmH2O
- Respiratory failure NOT fully explained by cardiac failure or fluid overload
2024 Global ARDS Definition Update
A 2024 consensus expanded Berlin to include:
- Non-intubated ARDS: Patients on HFNO (≥30 L/min) or NIV/CPAP (≥5 cmH2O) with PF ratio ≤300 or SF ratio ≤315
- Resource-limited settings: SpO2/FiO2 ratio can substitute for PaO2/FiO2
2. PHENOTYPING (NEW - ESICM 2023 Emphasis)
The 2023 ESICM guidelines introduced phenotype-guided management as a major advance:
Radiologic Phenotypes
| Phenotype | Pattern | PEEP Response |
|---|---|---|
| Focal ARDS | Lobar consolidation (usually pneumonia) | Low recruitability - avoid high PEEP, risk overdistension |
| Diffuse ARDS | Bilateral homogeneous opacities (sepsis, aspiration) | Higher recruitability - may benefit from higher PEEP |
Biologic Phenotypes
| Phenotype | Features | Implication |
|---|---|---|
| Hyperinflammatory | High IL-6, IL-8, TNF, shock, metabolic acidosis | Worse mortality; may respond to corticosteroids, simvastatin |
| Hypoinflammatory | Lower biomarkers, less shock | Better prognosis |
Key ESICM message: Treatment must follow phenotype, not habit.
3. MECHANICAL VENTILATION - LUNG-PROTECTIVE STRATEGY
Core Targets (ATS/ESICM - Strong/Conditional Recommendations)
| Parameter | Target | Rationale |
|---|---|---|
| Tidal Volume (VT) | 4-8 mL/kg predicted body weight | Prevents volutrauma |
| Plateau Pressure (Pplat) | ≤30 cmH2O | Prevents barotrauma |
| Driving Pressure (DP) | ≤15 cmH2O (DP = Pplat - PEEP) | Independent mortality predictor |
| SpO2 target | 88-95% | Avoid hyperoxia |
| PaO2 target | 55-80 mmHg | |
| pH | 7.30-7.45 | Permissive hypercapnia acceptable |
| Mechanical Power | Minimize (emerging target) | Total energy delivered to lung |
Permissive Hypercapnia
- Acceptable if pH >7.20
- Contraindicated in raised ICP, severe pulmonary hypertension
4. PEEP MANAGEMENT (ATS 2024 Updated Recommendation)
ATS 2024 - Conditional Recommendation (Low-Moderate Certainty):
Use higher PEEP WITHOUT lung recruitment maneuvers (vs. lower PEEP) in moderate-to-severe ARDS
ATS 2024 - Strong Recommendation (Moderate Certainty):
AGAINST prolonged lung recruitment maneuvers in moderate-to-severe ARDS (risk of hemodynamic compromise, barotrauma - from ART trial data)
PEEP Titration Methods
- PEEP/FiO2 tables (ARDSNet - standard)
- Esophageal pressure monitoring - targets positive transpulmonary pressure
- Electrical Impedance Tomography (EIT) - 2024 meta-analysis supports EIT-guided PEEP titration (PMID 38512400)
- Recruitment-to-Inflation (R/I) ratio - assesses individual recruitability
5. PRONE POSITIONING
Recommendation: Strong (ATS 2017, reaffirmed 2023 ESICM, maintained in ATS 2024)
- Indicated in moderate-severe ARDS (PF ratio <150)
- Duration: ≥12-16 hours/day
- Mechanism: Recruits dorsal lung, reduces V/Q mismatch, improves FRC, redistributes stress
- PROSEVA trial: 28-day mortality 16% vs 33% (NNT ~6)
- Should be initiated early (within 36 hours)
- ESICM 2023: Recommends prone even in patients on VV-ECMO (meta-analysis support)
Contraindications
- Unstable spine/pelvis fractures
- Open abdomen
- Elevated ICP (relative)
- Facial trauma (relative)
6. NEUROMUSCULAR BLOCKADE (NMB)
ATS 2024 - Conditional Recommendation (Low Certainty):
Suggest NMB in early severe ARDS (within 48 hours)
- Drug: Cisatracurium (continuous infusion 37.5 mg/hour)
- Duration: 48 hours maximum recommended
- Rationale: Reduces P-SILI (patient self-inflicted lung injury), ventilator dyssynchrony, oxygen consumption
- ACURASYS (2010): Mortality benefit at 90 days
- ROSE trial (2019): No mortality benefit with light sedation comparator - hence conditional (not strong) recommendation
- NMB still favored in: severe dyssynchrony, refractory hypoxemia, high drive breathing despite deep sedation
7. CORTICOSTEROIDS (ATS 2024 - NEW Recommendation)
ATS 2024 - Conditional Recommendation (Moderate Certainty):
Suggest corticosteroids for patients with ARDS (new in 2024 update)
This is a significant change from prior guidelines.
Dosing Regimens Used in Trials
| Regimen | Protocol |
|---|---|
| Dexamethasone (DEXA-ARDS trial) | 20 mg/day x5d → 10 mg/day x5d |
| Methylprednisolone | 1-2 mg/kg/day, taper over 2-4 weeks |
| Low-dose dexamethasone (COVID-STEROID2) | 6 mg/day x10d |
Key evidence:
- Reduces ventilator-free days, ICU LOS
- 2026 meta-analysis (PMID 41325621, Ann Intern Med): Corticosteroids reduce mortality in pneumonia/ARDS but increase infection risk
- Avoid in late ARDS (>14 days) - potential harm
- Adjust dose for hyperglycemia, secondary infections
8. VV-ECMO (ATS 2024 - Updated Recommendation)
ATS 2024 - Conditional Recommendation (Low Certainty):
Suggest VV-ECMO in selected patients with severe ARDS
Indications (ESICM 2023 & ATS 2024 criteria)
- PaO2/FiO2 <80 mmHg despite optimal conventional therapy, OR
- Severe hypercapnia: pH <7.25 with PaCO2 >60 mmHg
- Failure of prone positioning + NMB + high PEEP
- Early ARDS (<7 days)
- Reversible etiology
- Few futility risk factors (age, SOFA score, immunosuppression)
ATS vs. ESICM 2024 Divergence on ECMO
- ESICM 2023: Stronger recommendation, more defined center infrastructure requirements
- ATS 2024: Conditional recommendation, emphasizes patient selection
- Both agree: ECMO only after all conventional therapies exhausted
Evidence
- EOLIA trial: Stopped early, no significant mortality benefit (62-day mortality 35% vs 46%, p=0.07)
- Network meta-analysis (PMID 38842731, ICM 2024): VV-ECMO + prone positioning showed best survival in severe ARDS vs. prone alone or supine ventilation
- Requires high-volume ECMO center
9. FLUID MANAGEMENT
Recommendation: Conservative fluid strategy once shock is resolved
- Target: Euvolemia to mild negative balance
- FACTT trial: Conservative strategy → more ventilator-free days (no mortality benefit)
- Use CVP, urine output, lung US to guide
- Avoid aggressive fluid resuscitation after initial resuscitation phase
- Diuresis actively if fluid-overloaded and hemodynamically stable
10. ADJUNCT THERAPIES
Inhaled Pulmonary Vasodilators
| Agent | Effect | Recommendation |
|---|---|---|
| Inhaled NO | Improves oxygenation (V/Q) | No mortality benefit; use as bridge to prone/ECMO |
| Inhaled Epoprostenol | Same as iNO | Alternative to iNO |
High-Frequency Oscillatory Ventilation (HFOV)
- NOT recommended (OSCILLATE + OSCAR trials showed harm/no benefit)
- ATS 2017/2024: Recommend against HFOV
Airway Pressure Release Ventilation (APRV)
- Insufficient evidence for routine use
Statins, Beta-agonists, Surfactant
- Not recommended - multiple trials failed to show benefit
Sivelestat (Neutrophil Elastase Inhibitor)
- Used in Japan/Korea for ARDS
- 2025 meta-analyses show some benefit in septic ARDS - not yet standard of care globally
11. SEDATION & ANALGESIA (PADIS 2025 Update)
2025 PADIS guideline update (PMID 39982143):
- Prioritize analgesia-first approach
- Lightest effective sedation (RASS -1 to 0) unless:
- Severe ARDS needing NMB
- Refractory dyssynchrony
- Prone positioning
- Propofol or dexmedetomidine preferred over benzodiazepines for sedation
- Daily spontaneous awakening trials (SAT) + spontaneous breathing trials (SBT)
12. WEANING FROM MECHANICAL VENTILATION
- SAT + SBT bundle daily when condition improving
- T-piece or PS trial before extubation
- HFNO post-extubation reduces reintubation in high-risk patients
- SBT failure - return to full support, re-address reversible causes
13. SUMMARY: SEVERITY-BASED MANAGEMENT ALGORITHM
ALL ARDS:
├── Lung-protective ventilation (VT 4-8 mL/kg PBW, Pplat ≤30, DP ≤15)
├── Conservative fluids (after resuscitation)
├── Analgesia-first sedation (PADIS 2025)
├── Treat underlying cause
│
├── MODERATE-SEVERE (PF <150):
│ ├── Prone positioning ≥16h/day (STRONG recommendation)
│ ├── Higher PEEP (individualized, without prolonged LRM)
│ ├── Corticosteroids (conditional - ATS 2024 NEW)
│ └── NMB if early severe + dyssynchrony (conditional)
│
└── SEVERE REFRACTORY (PF <80, failing above):
├── Inhaled NO/epoprostenol as bridge
└── VV-ECMO at specialized center (conditional)
14. KEY 2024-2025 UPDATES SUMMARIZED
| Topic | What Changed |
|---|---|
| Corticosteroids | Now conditionally recommended (ATS 2024) |
| VV-ECMO | Updated selection criteria; network meta-analysis supports prone + ECMO combination |
| PEEP | Higher PEEP favored but prolonged LRM strongly discouraged |
| NMB | Conditional (not strong) due to ROSE trial; still used in select severe ARDS |
| Phenotyping | ESICM 2023 emphasizes focal vs. diffuse and hyper- vs. hypoinflammatory phenotypes |
| HFOV | Confirmed: do not use |
| Global definition | Non-intubated ARDS now recognized; resource-limited criteria added |
| EIT-guided PEEP | Growing evidence for individualized PEEP titration |
Key Sources:
- ATS 2024 Clinical Practice Guideline - Qadir et al., AJRCCM 2024 (PMID 38032683)
- ESICM 2023 Guidelines - Grasselli et al., Intensive Care Med 2023 (PMID 37326646)
- Network meta-analysis VV-ECMO vs. prone (PMID 38842731, ICM 2024)
- Corticosteroids meta-analysis (PMID 41325621, Ann Intern Med 2026)
- EIT-guided PEEP meta-analysis (PMID 38512400, ICM 2024)
- Harrison's Principles of Internal Medicine 22E (2025)
- Sabiston Textbook of Surgery; Fishman's Pulmonary Diseases and Disorders
This is a shared conversation. Sign in to Orris to start your own chat.